Insilico biological evaluation of newly synthesized 1'-(4-Bromophenyl)-4'-{4-[(2-oxo-1,2,3,4-tetrahydronaphthalen-2-ylidene) methyl] phenyl}-3'',4''-dihydroacenaphthylene-1-spiro-2'-pyrrolidine-3'-spiro-2''-naphthalene-2,1''(1H,2''H)-dione against fungal target

Fungal infection is the commnest problem everywhere. Depending on the types of starin involves the strategy applies. Various spectral antibiotics have been incorporated as antifungals but fail to inhibit. This pilot study establishes the new synthesied compound 1'-(4-Bromophenyl)-4'-{4-[(2- oxo-1,2,3,4-tetrahydronaphthalen-2-ylidene)methyl]phenyl}-3'',4''- dihydroacenaphthylene-1-spiro-2'-pyrrolidine-3'-spiro-2''-naphthalene- 2,1''(1H,2''H)-dione tested against the fungal target. Selected target retrieved from database and selected using biosynthetic pathways by using the cellular mechanism. This can be act as a check point to interrupt the pathway. Newly introduced pyrolidine based compound were dock with the glucose 6 phosphate synthase insilico docking tools and analyzed by X ray crystallography. Docking by molegro virual docker (MVD) shows good docking score and poses. It shows -141kcal/mol in first pose which considers as a based score and structure based binding site. In conclusion, the synthesized compound can designate as drug.